The Experts below are selected from a list of 312 Experts worldwide ranked by ideXlab platform
D Kolokithas - One of the best experts on this subject based on the ideXlab platform.
-
vancomycin resistant Gram Positive Cocci risk factors for faecal carriage
Journal of Hospital Infection, 1997Co-Authors: Gopal G Rao, F Ojo, D KolokithasAbstract:Abstract This case-control study was undertaken to identify the risk factors for the gastrointestinal carriage of vancomycin-resistant, Gram-Positive Cocci (VRGPC) including vancomycin-resistant enteroCocci (VRE). Use of oral vancomycin ( P = 0·003) or cephalosporins ( P = 0·03) and prolonged duration of stay in the hospital ( P = 0·02) were found to be the significant risk factors. Other previously suggested risk factors such as location of the patients and presence of central venous or arterial lines were not significantly associated with carriage of VRGPC. Judicious usage of glycopeptides (particularly oral vancomycin) and cephalosporins is likely to be the most effective way to prevent and control the spread of VRGPC and VRE.
Gopal G Rao - One of the best experts on this subject based on the ideXlab platform.
-
vancomycin resistant Gram Positive Cocci risk factors for faecal carriage
Journal of Hospital Infection, 1997Co-Authors: Gopal G Rao, F Ojo, D KolokithasAbstract:Abstract This case-control study was undertaken to identify the risk factors for the gastrointestinal carriage of vancomycin-resistant, Gram-Positive Cocci (VRGPC) including vancomycin-resistant enteroCocci (VRE). Use of oral vancomycin ( P = 0·003) or cephalosporins ( P = 0·03) and prolonged duration of stay in the hospital ( P = 0·02) were found to be the significant risk factors. Other previously suggested risk factors such as location of the patients and presence of central venous or arterial lines were not significantly associated with carriage of VRGPC. Judicious usage of glycopeptides (particularly oral vancomycin) and cephalosporins is likely to be the most effective way to prevent and control the spread of VRGPC and VRE.
F Ojo - One of the best experts on this subject based on the ideXlab platform.
-
vancomycin resistant Gram Positive Cocci risk factors for faecal carriage
Journal of Hospital Infection, 1997Co-Authors: Gopal G Rao, F Ojo, D KolokithasAbstract:Abstract This case-control study was undertaken to identify the risk factors for the gastrointestinal carriage of vancomycin-resistant, Gram-Positive Cocci (VRGPC) including vancomycin-resistant enteroCocci (VRE). Use of oral vancomycin ( P = 0·003) or cephalosporins ( P = 0·03) and prolonged duration of stay in the hospital ( P = 0·02) were found to be the significant risk factors. Other previously suggested risk factors such as location of the patients and presence of central venous or arterial lines were not significantly associated with carriage of VRGPC. Judicious usage of glycopeptides (particularly oral vancomycin) and cephalosporins is likely to be the most effective way to prevent and control the spread of VRGPC and VRE.
V. L. Yu - One of the best experts on this subject based on the ideXlab platform.
-
New antimicrobial agents as therapy for resistant Gram-Positive Cocci
European Journal of Clinical Microbiology & Infectious Diseases, 2008Co-Authors: J. R. Lentino, M. Narita, V. L. YuAbstract:Vancomycin- and methicillin-resistant Gram-Positive Cocci have emerged as an increasingly problematic cause of hospital-acquired infections. We conducted a literature review of newer antibiotics with activity against vancomycin-resistant and methicillin-resistant Gram-Positive Cocci. Quinupristin/dalfopristin, linezolid, daptomycin, and tigecycline have in vitro activity for methicillin-resistant staphyloCocci and are superior to vancomycin for vancomycin-resistant isolates. Dalbavancin, telavancin, and oritavancin are new glycopeptides that have superior pharmacodynamic properties compared to vancomycin. We review the antibacterial spectrum, clinical indications and contraindications, pharmacologic properties, and adverse events associated with each of these agents. Daptomycin has rapid bactericidal activity for Staphylococcus aureus and is approved for use in bacteremia and right-sided endocarditis. Linezolid is comparable to vancomycin in patients with methicillin-resistant S. aureus (MRSA) pneumonia and has pharmacoeconomic advantages given its oral formulation. Quinupristin/dalfopristin is the drug of choice for vancomycin-resistant Enterococcus faecium infections but has no activity against Enterococcus faecalis . Tigecycline has activity against both enterococcus species and MRSA; it is also active against Enterobacteriaceae and anaerobes which allows for use in intra-abdominal and diabetic foot infections. A review of numerous in vitro and animal model studies shows that interaction between these newer agents and other antistaphylococcal agents for S. aureus are usually indifferent (additive).
Kasper Karmark Iversen - One of the best experts on this subject based on the ideXlab platform.
-
Risk for infective endocarditis in bacteremia with Gram Positive Cocci
Infection, 2020Co-Authors: Malene Højgaard Andersen, Sarah Louise Kjølhede Holle, Christine Falk Klein, Niels Eske Bruun, Magnus Arpi, Henning Bundgaard, Niels Tønder, Kasper Karmark IversenAbstract:Purpose Infective endocarditis (IE) is a serious complication of bacteremia and is most often caused by Gram Positive Cocci. We investigated the prevalence of IE in patients where echocardiography was encouraged when bacteremia with Gram Positive Cocci was present. Methods The study included patients with Gram Positive Cocci bacteremia hospitalized at two Danish hospitals between March and December 2016. Information concerning echocardiography, demographics and bacterial species was collected from the patients’ medical files. Patients without echocardiography were followed for 6 months in order to confirm or reject possible IE. Results The study included 585 patients with Gram Positive Cocci bacteremia, and echocardiography was performed in 414 (71%) of them. The prevalence of IE in patients with high risk bacteremia, i.e. Staphylococcus aureus, non-beta-hemolytic streptoCocci, Enterococcus faecalis, and coagulase-negative staphyloCocci was 16%. Patients with Enterococcus faecalis had the highest prevalence of IE (33%) followed by non-beta-hemolytic streptoCocci (23%) and Staphylococcus aureus (12%). Among low risk bacteremia the prevalence of IE was 1%. The mean age of patients with IE was 74 years (SD 12.9) and 71% were male. Conclusion These findings strongly support routine echocardiography in patients with high risk bacteremia and non-performance of echocardiography in patients with low risk bacteremia.
